ScreenPoint Medical Announces Key Senior Leadership Hire - Vice President Of Sales for the US

Share Article

ScreenPoint Medical is excited to announce the addition of Nicki Bryan to the international team to support Transpara - the first FDA cleared AI breast AI solution for both 2D and 3D mammography.

Nicki Bryan joins ScreenPoint Medical as VP of Sales for the US

I am looking forward to bringing the undoubted benefits of Transpara to breast radiologists and their patients in the United States

ScreenPoint Medical of The Netherlands is pleased to announce the appointment of Nicki Bryan as the VP of Sales for the US. Nicki, a Masters of Health Informatics Healthcare Informatics graduate of Chatham University in Pittsburgh, Pennsylvania, joins the company at a very exciting time for their main product, Transpara artificial intelligence for mammography.

Nicki was a key member of the Fujifilm Medical Systems organization in the USA for seven years, the majority of that time as the National Director of Women's Health. During that time, her team supported Women's Health customers who were implementing 3D mammography into their practices, focusing on workflow both from a patient flow and an IT perspective. An important element of that task was the emphasis on equipping customers with the necessary IT environment and knowledge to support the impact of 3D mammography.

In her new challenge she will work alongside ScreenPoint’s distribution partners Volpara Solutions and Siemens Healthineers to bring the benefits of Transpara to the market.

Chief Operating Officer of ScreenPoint Medical Pieter Kroese comments, “Nicki’s appointment comes at a very strategic time for Transpara. Following FDA clearance for our 3D solution in March, which complements the existing 2D approval, Transpara is set to become the leading mammography AI decision support system in the USA.

Transpara is the only breast AI product that has both 2D and 3D FDA clearance and will be rolled out in 2020.
Nicki, with her drive and motivation, will lead that dynamic. We realise that the healthcare market is dominated by the Covid19 situation, but breast cancer will not go away and the need for fast, effective diagnosis of the disease will be a constant for many years to come.”

Nicki Bryan comments, “The results of the clinical reader study ScreenPoint submitted to the FDA are very impressive. The study not only demonstrated that Transpara helped to improve the accuracy of radiologists when reading 3D mammograms but also, it significantly reduced 3D reading time to about 35 seconds per exam. The ScreenPoint team understands that reading the number of images presented within a 3D mammography study is very challenging for our radiologists leading to burn out and unpredictable productivity. Transpara software changes that dynamic and by integration into their reading workstations, workflow is much improved.

I am looking forward to bringing the undoubted benefits of Transpara to breast radiologists and their patients in the United States.”

To learn more about how ScreenPoint Medical could help you with our new COVID-19 initiatives, please visit https://screenpoint-medical.com/covid-19-update/ or contact us directly on info@screenpointmed.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Lee
@screenpointmed
Follow >
Visit website